KARUNA THERAPEUTICS INC (KRTX) Stock News
NASDAQ:KRTX - Nasdaq - US48576A1007 - Common Stock - Currency: USD
KRTX Latest News, Press Relases and Analysis
Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.
Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb
Karuna Therapeutics (KRTX) experienced a temporary stock decline of 7.6%, but has since recovered to a 2% loss.
Karuna Therapeutics GAAP EPS of -$3.01 misses by $0.29 (NASDAQ:KRTX)
Karuna Therapeutics reports Q4 financial results, with a GAAP EPS of -$3.01, missing expectations by $0.29.
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
Mental Health Mavericks: 3 Stocks Changing the Game
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Bristol Myers stock cut at Redburn Atlantic (NYSE:BMY)
Redburn Atlantic downgrades Bristol-Myers Squibb (BMY) due to headwinds against its products despite the company's recent buyout deals. Read more here.
Karuna’s KarXT is Evaluate's most anticipated drug for 2024
Evaluate Vantage ranks Karuna Therapeutics'(KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.
Karuna’s KarXT tops Evaluate’s most anticipated drug list (NYSE:BMY)
Evaluate Vantage ranks Karuna Therapeutics' (KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.
Bristol-Myers almost lost Karuna buyout to third party (NYSE:BMY)
Bristol Myers Squibb (BMY) successfully fought to acquire Karuna Therapeutics (KRTX) in a $14B deal, outmaneuvering another large pharma bidder. Read more here.
Mentions: BMY
Bristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)
Bristol Myers Squibb (BMY) reportedly expects to launch 16 new products by the end of the decade, but will be looking for smaller deals after its 2023 shopping
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Bristol-Myers Squibb stock cut to Neutral at BofA (NYSE:BMY)
Bank of America downgrades Bristol-Myers Squibb (BMY) to Neutral due to concerns over upcoming patent expiries. Read more here.
What's in store for biotech M&A and IPOs in 2024? (NYSE:BMY)
Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
The major indexes boast big annual gains with the Dow at record highs.